AG真人官方

Telix H1 2025 Results: Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 鈥淭elix鈥�) today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025.

An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025).听听听

Participants can register for the webcast at the following link:

Participants can register for the teleconference here:

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on , and

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email:

Telix Investor Relations (U.S.)鈥�听
Annie Kasparian鈥���
Telix Pharmaceuticals Limited鈥���
Director Investor Relations and Corporate Communications鈥���
Email: 听

This announcement has been authorized for release by Telix Pharmaceuticals Limited鈥檚 Company Secretary, Genevieve Ryan.听听

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.听

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. 鈥疶o the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 鈥渕ay鈥�, 鈥渆xpect鈥�, 鈥渋ntend鈥�, 鈥減lan鈥�, 鈥渆stimate鈥�, 鈥渁nticipate鈥�, 鈥渂elieve鈥�, 鈥渙utlook鈥�, 鈥渇orecast鈥� and 鈥済uidance鈥�, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix鈥檚 good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix鈥檚 business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix鈥檚 business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix鈥檚 preclinical and clinical trials, and Telix鈥檚 research and development programs; Telix鈥檚 ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix鈥檚 product candidates, manufacturing activities and product marketing activities; Telix鈥檚 sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix鈥檚 product candidates, if or when they have been approved; Telix鈥檚 ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix鈥檚 expenses, future revenues and capital requirements; Telix鈥檚 financial performance; developments relating to Telix鈥檚 competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix鈥檚 business; and the pricing and reimbursement of Telix鈥檚 product candidates, if and after they have been approved. Telix鈥檚 actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the 庐 or 鈩� symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

漏2025 Telix Pharmaceuticals Limited. All rights reserved.